NICE Recommends Frontline Atezolizumab for Advanced Urothelial Cancer

November 1, 2017 – The UK’s National Institute for Health and Care Excellence (NICE) is recommending the use of atezolizumab for treatment-naïve patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-based therapy. Atezolizumab would be available for the Cancer Drugs Fund (CDF), but NICE is not recommending Roche’s PD-L1 inhibitor for routine National Health Service (NHS) use. The committee determined that … (leggi tutto)